Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13706025 | 0.74 | CYP3A4 (0.43) | CRHR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL289539 | 0.73 | TAS1R3 (0.33) | SMN1; SMN2 | |
| SCHEMBL13589306 | 0.72 | KDM4E (0.33) | CRHR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5423379 | 0.72 | L3MBTL1 (0.37) | CRHR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1316463 | 0.67 | KDR (0.52) | — | |
| SCHEMBL18258731 | 0.66 | LPO (0.43) | — | |
| SCHEMBL29877358 | 0.66 | KDR (0.51) | — | |
| SCHEMBL29070232 | 0.66 | KDR (0.51) | — | |
| SCHEMBL29788366 | 0.66 | KDR (0.51) | — | |
| SCHEMBL28848948 | 0.66 | KDR (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314243-B2 | by cyanating the aryl halides with potassium hexacyanoferrate(I) or (III) and using as catalysts, a palladium compound and a phosphine or biphosphine ligand; efficient reaction of less expensive aryl chloride on industrial scale; active catalyst; butylbis(adamantyl)phosphine or tri(t-butyl)phosphine | SALTIGO GMBH (DE) | 2012-11-20 | — | — | US | disclosed |
| US-20080194829-A1 | by cyanating the aryl halides with potassium hexacyanoferrate(I) or (III) and using as catalysts, a palladium compound and a phosphine or biphosphine ligand; efficient reaction of less expensive aryl chloride on industrial scale; active catalyst; butylbis(adamantyl)phosphine or tri(t-butyl)phosphine | SALTIGO GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
| EP-1930316-A1 | Method for catalytic manufacture of aromatic or heteroaromatic nitriles | Saltigo GmbH (DE) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194829-A1 | by cyanating the aryl halides with potassium hexacyanoferrate(I) or (III) and using as catalysts, a palladium compound and a phosphine or biphosphine ligand; efficient reaction of less expensive aryl chloride on industrial scale; active catalyst; butylbis(adamantyl)phosphine or tri(t-butyl)phosphine | TST, CBR3, ALK | CRHR1 3341/4885NPC1 4218/4885RAB9A 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.